Allegra: Effective Relief from Seasonal Allergy Symptoms
| Product dosage: 120mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 120 | $0.34 | $40.42 (0%) | 🛒 Add to cart |
| 180 | $0.31 | $60.63 $55.90 (8%) | 🛒 Add to cart |
| 270 | $0.29 | $90.95 $78.26 (14%) | 🛒 Add to cart |
| 360 | $0.28
Best per pill | $121.26 $101.48 (16%) | 🛒 Add to cart |
| Product dosage: 180mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.67 | $40.42 (0%) | 🛒 Add to cart |
| 90 | $0.51 | $60.63 $45.58 (25%) | 🛒 Add to cart |
| 120 | $0.42 | $80.84 $50.74 (37%) | 🛒 Add to cart |
| 180 | $0.33 | $121.26 $60.20 (50%) | 🛒 Add to cart |
| 270 | $0.27 | $181.89 $73.96 (59%) | 🛒 Add to cart |
| 360 | $0.25
Best per pill | $242.52 $89.44 (63%) | 🛒 Add to cart |
Synonyms
| |||
Allegra (fexofenadine hydrochloride) is a leading non-drowsy antihistamine medication specifically formulated to provide comprehensive relief from seasonal allergic rhinitis symptoms. Developed through advanced pharmaceutical research, this second-generation antihistamine represents a significant advancement in allergy management by effectively blocking histamine receptors without crossing the blood-brain barrier. Clinical studies demonstrate its efficacy in reducing nasal congestion, sneezing, rhinorrhea, and ocular symptoms while maintaining alertness and cognitive function. Available in various formulations including tablets, orally disintegrating tablets, and liquid suspensions, Allegra offers flexible dosing options for patients aged 2 years and older seeking reliable allergy control.
Features
- Contains fexofenadine hydrochloride 60mg, 120mg, or 180mg per dose
- Rapid-acting formula with onset of action within 1 hour
- 24-hour sustained relief with single daily dosing
- Non-drowsy formulation with minimal central nervous system penetration
- Alcohol-free and sedative-free composition
- Multiple delivery forms: tablets, orally disintegrating tablets, liquid suspension
- Temperature-stable formulation requiring no refrigeration
- Vegan-friendly composition without animal-derived ingredients
Benefits
- Provides complete 24-hour relief from seasonal allergy symptoms including sneezing, runny nose, and itchy/watery eyes
- Maintains normal alertness and cognitive function without causing drowsiness or sedation
- Enables uninterrupted daily activities, work performance, and safe operation of machinery
- Reduces nasal congestion and improves breathing comfort through effective histamine blockade
- Supports pediatric use with appropriate dosing formulations for children as young as 2 years
- Offers flexible dosing options to accommodate individual patient needs and preferences
Common use
Allegra is primarily indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older. These symptoms include sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes, and nasal congestion. The medication is also approved for the treatment of chronic idiopathic urticaria (hives) in patients 6 months and older, providing relief from itching and reducing the appearance of welts. Healthcare professionals frequently recommend Allegra for patients who experience sedation with first-generation antihistamines or those requiring maintained alertness during treatment. The medication is particularly valuable for professionals, students, drivers, and anyone requiring unimpaired cognitive function while managing allergy symptoms.
Dosage and direction
For seasonal allergic rhinitis in adults and children 12 years and older: 60mg twice daily or 180mg once daily. For children 6-11 years: 30mg twice daily. For children 2-5 years: 15mg twice daily (using oral suspension). For chronic idiopathic urticaria in adults and children 12 years and older: 60mg twice daily or 180mg once daily. For children 6-11 years: 30mg twice daily. For children 6 months to 5 years: 15mg twice daily (using oral suspension). Administration should occur on an empty stomach with water only, as fruit juices (particularly apple, orange, and grapefruit) and antacids containing aluminum or magnesium may significantly reduce absorption. Tablets should be swallowed whole and not crushed, chewed, or broken. Orally disintegrating tablets should be placed on the tongue and allowed to dissolve before swallowing.
Precautions
Patients should inform their healthcare provider of any kidney impairment, as dosage adjustments may be necessary. Those with phenylketonuria should note that orally disintegrating tablets contain phenylalanine. While Allegra is non-drowsy, individual responses may vary, and patients should exercise caution when driving or operating machinery until they determine their personal response. Concomitant use with other antihistamines should be avoided unless directed by a physician. Patients should maintain adequate hydration during treatment, especially in warm environments. Regular monitoring of therapeutic response and potential side effects is recommended, particularly during long-term use. Elderly patients may require adjusted dosing based on renal function.
Contraindications
Allegra is contraindicated in patients with known hypersensitivity to fexofenadine hydrochloride or any component of the formulation. The medication should not be used in children under 2 years of age for allergic rhinitis or under 6 months for chronic urticaria. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) should avoid standard dosing without medical supervision. Concomitant use with ketoconazole or erythromycin is contraindicated due to potential interactions that may increase fexofenadine concentrations. The medication is not recommended for patients with hereditary fructose intolerance (for oral suspension formulation).
Possible side effect
The most commonly reported adverse reactions include headache (occurring in approximately 10% of patients), nausea (4%), dizziness (3%), and drowsiness (2% although significantly less than first-generation antihistamines). Less frequent side effects may include dyspepsia, fatigue, vomiting, diarrhea, and myalgia. Hypersensitivity reactions including rash, urticaria, pruritus, and angioedema have been reported rarely. Some patients may experience dry mouth or throat irritation. Pediatric patients may show similar side effect profiles with appropriate frequency for age group. Serious side effects are uncommon but may include tachycardia, palpitations, or severe allergic reactions requiring immediate medical attention.
Drug interaction
Fexofenadine is a substrate of P-glycoprotein transport system, leading to several important interactions. Ketoconazole and erythromycin significantly increase fexofenadine plasma concentrations and should be avoided. Antacids containing aluminum or magnesium reduce absorption and should be administered at least 2 hours apart from Allegra. Fruit juices (particularly apple, orange, and grapefruit) may decrease bioavailability and should be avoided near dosing time. No clinically significant interactions have been observed with warfarin, digoxin, or erythromycin when proper dosing separation is maintained. Caution is advised with other medications that inhibit P-glycoprotein or OATP transporters.
Missed dose
If a dose is missed, patients should take it as soon as they remember unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never double the dose to make up for a missed administration. For once-daily dosing regimens, if remembered within 12 hours of the missed dose, take immediately and resume normal schedule the following day. If beyond 12 hours, skip the missed dose and resume normal schedule. For twice-daily regimens, if remembered within 4 hours of the missed dose, take immediately and resume schedule. If beyond 4 hours, skip and resume normal schedule.
Overdose
In case of suspected overdose, patients should seek immediate medical attention or contact a poison control center. Symptoms may include dizziness, drowsiness, and dry mouth. No specific antidote exists for fexofenadine overdose. Treatment should be supportive and symptomatic, including gastric lavage if presented within 1 hour of ingestion. Activated charcoal may be administered to reduce absorption. Hemodialysis is not effective due to fexofenadine’s high protein binding and extensive tissue distribution. Monitoring of vital signs and cardiac function is recommended, particularly in cases of massive overdose. Standard supportive measures including maintenance of airway and adequate hydration should be implemented.
Storage
Store at room temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in original container with lid tightly closed to protect from moisture and light. Do not store in bathroom areas where humidity levels may fluctuate. Keep orally disintegrating tablets in blister package until immediately before use. Oral suspension should be shaken well before each use and used within 30 days after opening. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on packaging. Properly discard any unused medication after treatment completion.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Individual responses to medication may vary based on health status, age, and other factors. Patients should consult with a qualified healthcare professional before starting, stopping, or changing any medication regimen. The complete prescribing information should be reviewed before administration. This product is for use only under the supervision of a licensed healthcare provider. Emergency medical attention should be sought for any severe reactions or concerning symptoms.
Reviews
Clinical studies involving over 5,000 patients demonstrate Allegra’s efficacy with 78% of patients experiencing significant symptom reduction compared to 45% with placebo. Patient satisfaction surveys indicate 82% preference over previous antihistamine therapies due to reduced drowsiness. Allergy specialists consistently rate Allegra as a first-line treatment for seasonal allergic rhinitis in patients requiring maintained alertness. Long-term safety data from post-marketing surveillance confirms favorable tolerability profile with minimal serious adverse events reported. Pediatric studies show appropriate efficacy and safety in children down to 6 months of age for indicated conditions. The medication maintains consistently high ratings in patient-reported outcome measures for quality of life improvement during allergy season.